Assessing the effects of atypical antipsychotics on negative symptoms

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 12, 1998, Pages 28-34

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

CLINICAL FEATURE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; DELUSIONS; DEPRESSIVE DISORDER; HALLUCINATIONS; HUMANS; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0031690526     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Strauss JS, Carpenter WT Jr, Bartko JJ. Diagnosis and understanding of schizophrenia, III: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974;11:61-69
2. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980;280:66-68
3. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39:789-794
4. Andreasen NC, Flaum M, Swayze VW, et al. Positive and negative symptoms in schizophrenia: a critical appraisal. Arch Gen Psychiatry 1990;47: 615-621
5. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-452
6. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583
7. Miller DD, Perry PJ, Cadoret RJ, et al. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
8. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
9. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
10. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474
11. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
12. Tandon R, Harrigan E, Zorn S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997;4: 159-177
13. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982;39:784-788
14. Marder SR. Psychiatry rating scales. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 1. 6th ed. Baltimore, Md: Williams & Wilkins: 1995:622
15. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:262-276
16. Andreasen NC, Arndt S, Alliger R, et al. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995;52: 341-351
17. Flaum M, Andreasen N. The reliability of distinguishing primary vs. secondary negative symptoms. Compr Psychiatry 1995;36:421-427
18. Tandon R, Greden JF. Negative symptoms of schizophrenia: need for conceptual clarity. Biol Psychiatry 1991;30:321-325
19. Tandon R, Goldman R, DeQuardo JR, et al. Covariance of positive and negative symptoms during clozapine treatment in schizophrenia. J Psychiatr Res 1993;27:341-347
20. Tandon R, Jibson MD, Taylor SF, et al. The pathophysiology of positive and negative symptoms in schizophrenia. In: Shriqui C, Nasrallah HA, eds. Contemporary Issues in the Treatment of Schizophrenia. Washington DC: American Psychiatric Press;1995:109-126
21. Andreasen N, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 1993;49:615-623
22. Tandon R, Karam-Hage M, Goldman M, et al. Negative symptoms improve in deficit and nondeficit schizophrenia [abstract]. Biol Psychiatry 1996;39:545
23. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
24. Tandon R, Goldman R, Goodson J, et al. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry 1990;27:1323-1326
25. Tandon R, Ribeiro SCM, DeQuardo JR, et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry 1993;34:495-497
26. Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:563-565
27. van Kammen DP, Hommer DW, Malas KL. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state-dependent? Neuropsychobiology 1987;18:113-117
28. Jibson MD, Tandon R. A summary of new research findings on the new antipsychotic drugs. Essential Pharmacol 1996;1:27-37
29. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789-796
30. Kane JM, Honigfeld G, Singer J, et al. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67
31. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
32. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
33. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
34. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
35. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
36. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
37. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
38. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychiatric Times 1996;August supplement:7-13
39. Martin J, Gomez JC, García-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997;58:479-483
40. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207-213
41. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry 1994;55 (5, suppl):22-28
42. Smith RC, Chua JW, Lipetsker B, et al. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57:460-466
43. Rossi A, Manicini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40-43
44. Möller HJ, van Praag HM, Aufdembrinke B, et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology (Berl) 1994;115: 221-228
45. Möller HJ, Müller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-49
46. Möller HJ, Müller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 1997;247:1-5
47. Beasley CM Jr, Tollefson GD, Tran PV, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123